CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 38 enrolled
Drug / intervention
lavender and chamomile essential oilsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03097484
NCT03097484Phase 3Completed
CompareCT.gov

The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels

John M. Daniel·interventional·Posted Mar 31, 2017·Updated May 14, 2019

In Brief

A Phase 3 clinical trial evaluating lavender and chamomile essential oils for Neonatal Abstinence Syndrome and Aromatherapy. Completed, enrolled 38 participants across 1 site.

Detailed Summary

Determine the effectiveness of lavender and chamomile aromatherapy of mitigation of symptoms of Neonatal Abstinence Syndrome

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeonatal Abstinence Syndrome, Aromatherapy
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 31, 2017
Enrollment StartJul 25, 2015
Primary CompletionApr 30, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.3 years ago

Interventions

lavender and chamomile essential oilsdrug

Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.